Observing and analyzing birdshot chorioretinopathy
Longitudinal Cohort Study of Patients With Birdshot Chorioretinopathy.
This study looks at the symptoms and effects of birdshot chorioretinopathy in patients to see how it impacts their vision and quality of life, while also trying to find genetic factors that might be linked to the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, Île-de-France Region) |
| Trial ID | NCT05153057 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze the clinical features of patients with birdshot chorioretinopathy (BCR), a bilateral inflammatory ocular disease. It will utilize various imaging techniques to assess the impact of the disease on the retina and choroid, alongside standardized visual function assessments and quality of life evaluations. Additionally, the study seeks to identify predisposing immunogenetic factors associated with BCR, particularly focusing on the HLA-A29 allele. Through these analyses, the study hopes to better categorize the heterogeneous presentations of the disease.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with bilateral birdshot chorioretinopathy exhibiting specific ocular lesions.
Not a fit: Patients with infectious, neoplastic, or other inflammatory diseases that cause multifocal choroidal lesions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management strategies for patients with birdshot chorioretinopathy.
How similar studies have performed: While there have been studies on birdshot chorioretinopathy, this specific approach focusing on immunogenetic factors and detailed clinical analysis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Bilateral disease 2. Presence of at least three peripapillary "birdshot lesions" inferior or nasal to the optic disk in one eye 3. Low-grade anterior segment intraocular inflammation (defined as ≤ 1+cells in the anterior chamber) 4. Low grade vitreous inflammatory reaction (defined as ≤ 2+ vitreous haze‡) Supportive findings 1\. HLA-A29 positivity 2. Retinal vasculitis 3. Cystoid macular edema Exclusion Criteria: 1. Keratic precipitates 2. Posterior synechiae 3. Presence of infectious, neoplastic, or other inflammatory diseases that can cause multifocal choroidal lesions
Where this trial is running
Paris, Île-de-France Region
- Ophtalmopôle, Hôpital Cochin — Paris, Île-de-France Region, France (Recruiting)
Study contacts
- Principal investigator: Antoine BREZIN, PhD & MD — Université de Paris, Ophtalmopôle, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris.
- Study coordinator: Souhila KECILI, MSc
- Email: souhila.kecili@aphp.fr
- Phone: +33 1 58412898
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.